Release Date: 29/06/10 16:58 Summary: CQT: Supplementary Bidder's Statement Price Sensitive: Yes Download Document 4.16MB Download
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress